Clinical Trials
3 trialsNCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting